Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics
Pfizer is set to pay $330 million upfront to Starna Therapeutics to take exclusive rights to three pre-IND in vivo CAR-T assets in autoimmune disease outside of Greater China. Plus, the pharma will also get ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.